A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Exclusion Criteria12

• History of any clinically important disease or disorder
• History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones
• Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day
• Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
• Any clinically significant abnormal findings in vital signs
• Any clinically significant abnormalities on 12-lead ECG
• HbA1c ≥6.5% (≥48 mmol/mol)
• Evidence of renal impairment
• Females who are pregnant or lactating.
• Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer)
• Participants who report to have previously received AZD6234.
• Use of any prescribed or non-prescribed medication